New hyperpolarized-13C MRI instrumentation and methods enabled phase II clinical studies on 17 prostate cancer patients using 3D dynamic CS-EPSI with 0.5cm3 spatial and 2s time resolution. New manufacturing processes for 13C-pyruvate provided more consistent polarization levels, pyruvate concentrations, radical filtrations for reliable and safe patient injections. Improved quantitative methods were designed and implemented for reproducible kinetic modeling, correction for receiver profile, and peak detection, accounting for B0 inhomogeneity and noise characteristics. These studies have shown the ability to detect high pyruvate-to-lactate conversion rates in biopsy confirmed prostate cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords